Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable ...

Olanzapine LAI (mdc-TJK / TEV-‘749) is an investigational, once-monthly, subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the ...